康灃生物科技（上海）股份有限公司 1 第一條 為了進一步健全康灃生物科技（上海）股份有限公司（以下簡稱「公 司」或「本公司」）董事和高級管理人員的選任，完善公司治理結構， 根據《中華人民共和國公司法》（以下簡稱「《公司法》」）、《香港聯合 交易所有限公司證券上市規則》（以下簡稱「《上市規則》」）以及公司 章程，公司特設立董事會（「董事會」）提名委員會（「提名委員會」）， 並制定本工作細則（「工作細則」）。 第二條 提名委員會是董事會按照公司董事會決議設立的專門委員會，主要 負責就公司董事、高級管理人員的人選、選擇標準和程式進行討論 並向董事會提出建議。 第三條 本工作細則所稱的董事和高級管理人員為： （一） 董事：公司執行董事、非執行董事、獨立非執行董事； （二） 高級管理人員：公司總經理、副總經理、財務負責人、董事 會秘書； （三） 提名委員會認為應當適用的其他人員。 第四條 提名委員會由三名或以上董事組成，其中獨立非執行董事佔過半 數。提名委員會成員由董事長、三分之一以上獨立非執行董事或二 分之一以上全體董事提名，經董事會全體董事過半數選舉產生和罷 免。 第五條 提名委員會設主席（「主席」）一名，由董事長 ...

康灃生物科技（上海）股份有限公司 董事會薪酬委員會工作細則 第一章 總則 第二章 人員組成 1 第一條 為了進一步健全康灃生物科技（上海）股份有限公司（以下簡稱「公 司」或「本公司」）的薪酬管理制度，不斷完善激勵機制等薪酬體系， 完善公司治理結構，根據《中華人民共和國公司法》（以下簡稱「《公 司法》」）、《香港聯合交易所有限公司證券上市規則》（以下簡稱「《上 市規則》」）以及《公司章程》，公司特設立董事會（「董事會」）薪酬委 員會（「薪酬委員會」），並制定本工作細則（「工作細則」）。 第二條 薪酬委員會是董事會按照董事會決議設立的專門委員會，主要負責 研究公司董事、高級管理人員的績效考核標準，進行考核並提出建 議；研究和審查公司董事、高級管理人員的薪酬政策和方案。 第三條 本細則所稱的董事是指在本公司領取薪酬的董事，高級管理人員是 指按照《公司章程》規定的由董事會聘任的總經理、副總經理、財務 負責人、董事會秘書以及董事會認定的其他高級管理人員。 第四條 本細則所稱薪酬是指董事會、高級管理人員從本公司獲取的包括基 本工資、考核工資、股權、期權及股份獎勵（如有）等形式的各種報 酬（「薪酬」）。 第五條 薪酬委員會 ...

康灃生物科技（上海）股份有限公司 董事會審核委員會工作細則 第一章 總則 第二章 人員組成 審核委員會召開或召集的會議，由審核委員會主席主持。審核委員 會主席不能履行職務或不履行職務時，由半數以上審核委員會委員 共同推舉的一名審核委員會委員主持。 1 第一條 為了進一步健全康灃生物科技（上海）股份有限公司（以下簡稱「公 司」或「本公司」）的決策功能，充分發揮審核委員會的監督作用，維 護審計工作獨立性，健全公司董事會（「董事會」）的審計、評價和監 督機制，確保公司董事會對公司的有效監督，完善公司治理結構， 根據《中華人民共和國公司法》（以下簡稱「《公司法》」）、《香港聯合 交易所有限公司證券上市規則》（以下簡稱「《上市規則》」）以及《公司 章程》，公司特設立董事會審核委員會（「審核委員會」），並制定本 工作細則（「工作細則」）。 第二條 審核委員會是董事會按照公司董事會決議設立的專門委員會，主要 負責公司內、外部審計的溝通、監督和核查工作，財務諮詢及其披 露的審閱，重大決策事項的監督和檢查工作，對董事會負責。 第三條 審核委員會由三名或以上非執行董事組成，其中獨立非執行董事佔 過半數。委員中至少應包含一名獨立非 ...

Financial Performance - Revenue increased from RMB 53.5 million in 2024 to RMB 95.3 million in 2025, representing a growth of 78.0%[3] - Gross profit rose to RMB 63.98 million in 2025, up 66.6% from RMB 38.41 million in 2024[2] - Net loss decreased significantly from RMB 111.3 million in 2024 to RMB 44.5 million in 2025, a reduction of 60.0%[5] - The company reported revenue from the sale of medical consumables and devices amounting to RMB 95,268,000 in 2025, a significant increase from RMB 53,531,000 in 2024, representing a growth of approximately 77.9%[27] - Other income decreased significantly to RMB 1,125,000 in 2025 from RMB 19,573,000 in 2024, primarily due to a reduction in government grants[31] - The company incurred a pre-tax loss of RMB 44,456,000 in 2025, an improvement from a loss of RMB 111,143,000 in 2024[34] - The company did not declare or pay any dividends during the year, consistent with the previous year[35] - The company reported a basic loss per share attributable to ordinary equity holders of the parent, calculated based on a weighted average of 239,110,000 shares outstanding for the year[36] Research and Development - Research and development expenses decreased from RMB 73.46 million in 2024 to RMB 30.44 million in 2025[6] - The company has established a comprehensive intellectual property portfolio with 180 patents and 40 patent applications as of December 31, 2025[69] - The company plans to accelerate clinical development and commercialization of in-progress products, focusing on minimally invasive cryo-intervention technologies[71] Regulatory Approvals and Product Development - The malignant stenosis cryoablation system received approval from the National Medical Products Administration in March 2025 and was commercialized in May 2025[5] - The asthma cryoablation system was granted breakthrough medical device designation by the U.S. FDA in July 2025[5] - The cardiac cryoablation system received approval from the National Medical Products Administration in December 2023, with commercialization expected in January 2024[48] - The Cryofocus cryoablation system, designed for hypertension treatment, is anticipated to receive approval by the second half of 2027[49] - The pulmonary hypertension cryoablation system is currently in preclinical research, with expected approval by the second half of 2029[50] - The COPD cryo-spray treatment system entered confirmatory clinical trials in March 2023, with registration documents expected to be submitted in the first half of 2027[51] - The asthma cryoablation system is also in confirmatory clinical trials, with registration documents expected to be submitted in the second half of 2027 and approval anticipated in the first half of 2029[52] - The benign stricture cryoablation system is expected to enter confirmatory clinical trials in January 2024, with product registration documents to be submitted to the National Medical Products Administration (NMPA) in the first half of 2027 and anticipated approval in the second half of 2027[54] - The lung nodule cryoablation system is currently in confirmatory clinical trials, with plans to submit registration documents to the NMPA in the second half of 2026 and expected approval in the second half of 2027[55] - The cough cryo-spray treatment system is in feasibility clinical trials, with expected registration submission to the NMPA in the second half of 2027 and anticipated approval in the second half of 2028[56] - The tuberculosis cryo-spray treatment system is also in feasibility clinical trials, with plans to submit registration documents to the NMPA in the second half of 2027 and expected approval in the second half of 2028[57] - The frozen adhesion treatment system received NMPA approval for its supporting cryotherapy equipment in December 2023 and for the disposable cryo-probe in January 2024, with commercialization planned for September 2024[58] - The bladder cryoablation system was approved by the NMPA in June 2022 and was commercialized in China in December 2022[59] - The gastric cryoablation system is currently in feasibility clinical trials, with expected registration submission to the NMPA in the first half of 2027 and anticipated approval in the first half of 2028[60] - The esophageal cryo-spray treatment system is in feasibility clinical trials, with plans to submit registration documents to the NMPA in the first half of 2027 and expected approval in the first half of 2028[61] Financial Position and Assets - Total assets decreased from RMB 98.16 million in 2024 to RMB 91.23 million in 2025[8] - The company's equity total decreased from RMB 78.93 million in 2024 to RMB 48.53 million in 2025[9] - Cash and cash equivalents decreased from RMB 45.46 million in 2024 to RMB 35.03 million in 2025[8] - Trade receivables remained at RMB 74,000, with a corresponding impairment of RMB 74,000, resulting in a net book value of zero[37][39] - Other receivables decreased from RMB 22,828,000 in 2024 to RMB 23,317,000 in 2025, with impairment losses reducing from RMB 901,000 to RMB 571,000[41] - Trade payables increased significantly from RMB 1,205,000 in 2024 to RMB 2,491,000 in 2025, indicating a rise in operational liabilities[42] - Other payables and accrued expenses rose from RMB 21,841,000 in 2024 to RMB 34,879,000 in 2025, reflecting increased operational costs[43] Corporate Governance and Compliance - The company has adopted a code of conduct for securities trading by directors and senior management, confirming compliance throughout the reporting period[101] - The audit committee, consisting of one non-executive director and two independent non-executive directors, has reviewed the financial reporting and internal control systems, ensuring compliance with relevant accounting standards[103] - The company has maintained compliance with the corporate governance code throughout the reporting period and will continue to monitor its governance practices[100] - The company has not purchased, sold, or redeemed any of its listed securities during the reporting period[102] - The company has proposed amendments to its articles of association to abolish the supervisory board, with the changes approved at the extraordinary general meeting[99] Market and Operational Strategy - The company operates primarily in mainland China, with nearly all revenue generated from the sale of medical consumables and devices in that region[24] - The company has a single reportable segment focused on the research and development of medical consumables and devices, with no further segment analysis provided[23] - The company focuses on innovative medical devices in minimally invasive cryotherapy, establishing high entry barriers for competitors[44] - The company aims to expand its market presence in vascular intervention and natural orifice transluminal endoscopic surgery (NOTES) for various diseases[44] Share Issuance and Financing - The company completed the issuance of 5,595,000 H shares in January 2026, raising approximately HKD 29.73 million[5] - The company announced a conditional agreement to issue 7,460,000 H-shares at a subscription price of HKD 5.36 per share, representing approximately 5.20% of the existing issued H-shares and 3.12% of the total issued shares as of the agreement date[106] - The total amount raised from the subscription agreement is approximately HKD 39.99 million, with a net amount of about HKD 39.73 million after expenses, equating to a net issue price of approximately HKD 5.33 per share[107] - The net proceeds from the subscription agreement are intended for research, production, and commercialization of minimally invasive products related to vascular intervention, respiratory intervention, and tumor intervention, with potential overseas business expansion[108] Employee and Operational Metrics - The company employed 174 full-time employees as of December 31, 2025, down from 276 in 2024, with total employee benefits expenses amounting to approximately RMB 74.3 million[96] - The company did not engage in any significant investments, acquisitions, or disposals of subsidiaries, associates, or joint ventures during the reporting period[93] - The company does not have any significant contingent liabilities, guarantees, or litigation threats as of December 31, 2025[92]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 董事會會議日期 康灃生物科技（上海）股份有限公司（「本公司」，連同其附屬公司統稱「本集團」） 董事（「董事」）會（「董事會」）茲宣佈謹定於2026年3月27日（星期五）召開董事會 會議，以（其中包括）審議及通過本集團截至2025年12月31日止年度之全年業績 及其發佈，以及審議派發末期股息之建議（如有）。 承董事會命 康灃生物科技（上海）股份有限公司 董事會主席 李克儉先生 香港，2026年3月17日 於本公告日期，董事會包括執行董事李克儉先生、朱軍先生及劉偉先生，非執行 董事呂世文先生及趙春生先生，以及獨立非執行董事高大勇博士、梁顯治先生、 覃正博士及胡赫男博士。 Cryofocus Medtech (Shanghai) Co., Ltd. 康灃生物科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6922） ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康灃生物科技（上海）股份有限公司 (「本公司」) (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06922 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 149,033,579 | RMB | | 1 RMB | | 149,033,579 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 149,033,579 | RMB | | 1 RMB | | 149,033,5 ...

Group 1: Stock Performance - The stock price of Kangfeng Biological-B has recently declined, with a notable drop of 3.41% on February 13 [2] - As of February 13, the stock price was 5.95 HKD, which is below both the 20-day and 30-day moving averages, indicating a weak short-term trend [3] Group 2: Financial Situation - The company reported a net loss attributable to shareholders of 23.81 million HKD for the first half of 2025, with a net profit margin of -53.26% [4] - The net cash flow from operating activities for the year 2024 was -82.91 million HKD, reflecting insufficient self-sustaining capability [4] Group 3: Capital and Technical Aspects - On January 30, 2026, the company completed a subscription agreement, issuing 5.595 million new shares at 5.36 HKD per share, raising approximately 29.73 million HKD, which accounts for about 2.29% of the expanded total share capital [3] - The MACD histogram is in negative territory, indicating a weak short-term trend, and the turnover rate on that day was only 0.02%, suggesting low market participation and liquidity issues [3] Group 4: Industry and Competitive Landscape - The company operates in the fast-evolving field of minimally invasive interventional devices, which requires high R&D investment and time to validate market acceptance of products [5] - The medical sector is experiencing differentiated performance, with variations in individual stock fundamentals leading to divergent trends [5]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康灃生物科技（上海）股份有限公司 (「本公司」) (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06922 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 143,438,579 | RMB | | 1 RMB | | 143,438,579 | | 增加 / 減少 (-) | | | 5,595,000 | | | RMB | | 5,595,000 | | 本月底結存 | | | 149,033,579 | RMB | | 1 R ...

Group 1 - The company, 康沣生物-B (06922), announced the issuance of 5.595 million H-shares through a subscription method, authorized at the annual general meeting of shareholders scheduled for June 20, 2025 [1]

Group 1 - The company 康沣生物-B (06922) announced the issuance of 5.595 million H-shares through a subscription method at the annual general meeting of shareholders scheduled for June 20, 2025 [1]